Navigation Links
Pixantrone Combination Therapy for First-line Treatment of,Aggressive Non-Hodgkin's Lymphoma Results in Reduction in Severe,Toxicities Including Heart Damage When Compared to,Doxorubicin-based Therapy

o clinical studies of pixantrone in aggressive NHL patients, RAPID and a phase III single agent trial, known as EXTEND. The EXTEND trial explores the role of single-agent treatment as a salvage regimen in patients with relapsed aggressive NHL who have failed at least two prior treatment regimens. Patients are randomized to receive either pixantrone or another single-agent drug of the physician's choice currently used for the treatment of this patient population. An interim look for the EXTEND trial is planned for later this year.

The Company is awaiting feedback from the FDA on the design of a new phase III trial of pixantrone for patients with indolent NHL. The trial, PIX303, will examine the complete remission rates and time to disease progression for the combination regimen of fludarabine, pixantrone and rituximab (FP-R) compared to the combination of fludarabine and rituximab (F-R) in the treatment of patients who have received at least one prior treatment for NHL. The trial is expected to enroll 300 patients.

About Pixantrone

Pixantrone is an investigational agent under development for the potential treatment of various hematological malignancies, solid tumors and immunological disorders. It was developed to improve the activity and safety of the anthracycline family of anti-cancer agents. Anthracyclines have been shown to be very active clinically in a number of tumor types. However, they are usually associated with cumulative heart damage that prevents them from being used in a large proportion of patients. Pixantrone has been designed to reduce the potential for these severe cardiotoxicities, as well as to potentially increase activity and permit simplified administration compared to the currently marketed anthracyclines.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For ad
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
3. Pixantrone Granted Fast Track Designation by FDA for Relapsed Indolent NHL Patients
4. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
5. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
6. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
7. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
8. Poniard Pharmaceuticals Announces Promising Data From Interim Safety Analysis of Phase 1 Combination Trials of Picoplatin in Colorectal and Prostate Cancers
9. Peregrine Pharmaceuticals Reports Positive Top-Line Results in Bavituximab Combination Therapy Trial in Advanced Cancer Patients
10. Intarcia Therapeutics Announces Presentation of Final Results From a Phase 2 Combination Study for the Treatment of Hepatitis C at the Digestive Disease Week Conference
11. Data Presented at ASH Demonstrate Nebivolol Lowers Blood Pressure as Long-Term Monotherapy and in Combination Therapy
Post Your Comments:
(Date:7/23/2014)... Announced at the 20 th  International ... seeks to increase access to a promising new HIV medicine ... conference in Melbourne today, the Medicines ... Sciences for tenofovir alafenamide (TAF), a promising new medicine currently ... India and China ...
(Date:7/23/2014)... PLAINS, N.Y. , July 23, 2014 /PRNewswire-USNewswire/ ... approval of idelalisib to treat patients with relapsed ... small lymphocytic lymphoma (SLL) is a significant advance ... Idelalisib, which goes by the trade name ... a protein that is highly expressed in many ...
(Date:7/23/2014)... PALO ALTO, Calif., July 23, 2014  Varian Medical ... net earnings of $1.02 per diluted share in the ... negatively impacted by about $0.06 per diluted share due ... a portion of Varian,s existing equity investment in Augmenix, ... Varian,s company-wide revenues totaled $748 million for the third ...
Breaking Medicine Technology:The Medicines Patent Pool (MPP) Broadens Collaboration with Gilead Sciences: Signs Licence for Phase III Medicine Tenofovir Alafenamide (TAF) 2The Medicines Patent Pool (MPP) Broadens Collaboration with Gilead Sciences: Signs Licence for Phase III Medicine Tenofovir Alafenamide (TAF) 3The Leukemia & Lymphoma Society Applauds FDA's Approval of Idelalisib To Treat Three Types of Blood Cancers 2Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 2Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 3Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 4Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 5Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 6Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 7Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 8Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 9Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 10
... , , MOUNTAIN VIEW, Calif., Dec. 29 ... developing innovative, next-generation medical therapies to address unmet needs in ... Drug Application (NDA) has been submitted to the U.S. Food ... drug for the treatment of obesity, including weight loss and ...
... , , REDWOOD CITY, Calif., Dec. 28 Codexis, ... Form S-1 with the U.S. Securities and Exchange Commission ("SEC") relating ... stock. The shares of common stock to be sold in ... certain of its stockholders. , Credit Suisse Securities (USA) LLC and ...
Cached Medicine Technology:VIVUS Submits Qnexa(R) New Drug Application to the FDA for the Treatment of Obesity 2VIVUS Submits Qnexa(R) New Drug Application to the FDA for the Treatment of Obesity 3VIVUS Submits Qnexa(R) New Drug Application to the FDA for the Treatment of Obesity 4VIVUS Submits Qnexa(R) New Drug Application to the FDA for the Treatment of Obesity 5Codexis, Inc. Files Registration Statement for Proposed Initial Public Offering 2
(Date:7/24/2014)... FL (PRWEB) July 24, 2014 The Arm ... to remove excess fat and skin from the upper arms ... soft tissues in the upper arm can become lax and ... Many people are embarrassed by the appearance of sagging upper ... ARC Plastic Surgery Aventura is now offering brachioplasty ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 “To care for ... widow, and his orphan.” The inspired quote is attributed to ... Department of Veterans Affairs (VA). And yet the reality of ... personnel in exchange for their service in times of conflict, ... who represents many veterans locked in a battle they never ...
(Date:7/24/2014)... 2014 American Sentinel University’s free ... Prevent the Three Infections That Make Up Two-Thirds ... go-to guide to help nurses minimize the occurrence ... basic prevention measures that every nurse should know ... for download at http://www.americansentinel.edu/blog/2014/05/13/strong-nursing-leadership-is-essential-to-reducing-hais/ . , “As ...
(Date:7/24/2014)... 2014 Skin management experts at FACE ... and innovative treatment, the Geneo™ 3-in-1 Super Facial, specifically ... fine lines and large pores, leaving skin looking radiant. ... to bring this treatment from Israel, and the first ... offer this exclusive treatment. , This innovative treatment ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 The Republic of ... a new CARDAMOM CRÈME BRÛLÉE TEA to celebrate “The Hundred-Foot ... Oprah Winfrey and Juliet Blake. A hundred-foot journey begins in ... cross over into a new realm that is far out ... small in physical distance that materially changes the course of ...
Breaking Medicine News(10 mins):Health News:How to Get Toned Arms With Arm Lift Procedure 2Health News:How to Get Toned Arms With Arm Lift Procedure 3Health News:LawyersandSettlements.com Interviews Veterans Benefits Attorney Shanin Specter about Recent VA Hospital Reports 2Health News:LawyersandSettlements.com Interviews Veterans Benefits Attorney Shanin Specter about Recent VA Hospital Reports 3Health News:LawyersandSettlements.com Interviews Veterans Benefits Attorney Shanin Specter about Recent VA Hospital Reports 4Health News:LawyersandSettlements.com Interviews Veterans Benefits Attorney Shanin Specter about Recent VA Hospital Reports 5Health News:New E-book Helps Nurses Identify and Prevent Three Most Common Healthcare Associated Infections 2Health News:New E-book Helps Nurses Identify and Prevent Three Most Common Healthcare Associated Infections 3Health News:FACE Skincare Medical Wellness Debuts Exclusive 3-in-1 Facial Treatment in Michigan 2Health News:The Republic of Tea Unveils New Tea Inspired by “The Hundred-Foot Journey” 2Health News:The Republic of Tea Unveils New Tea Inspired by “The Hundred-Foot Journey” 3
... Farm, South Africa, concluded that male circumcision could considerably ... the researchers studied the economical aspects of this approach ... new research is published in PLoS Medicine, and suggests ... in South Africa, mainly through savings on the cost ...
... that Health Care Workers (HCWs) in developing countries are particularly ... latent infection with tuberculosis, which is active. The infected ... ,One third of the world's population is ... most people, the bug causes no health problems and it ...
... a heart surgery years ago underwent the same procedure ... he is raring to get back to work after recuperating ... blood vessel called aorta, in his heart ,that was torn. ... surgical procedure for a condition called dissecting aortic aneurysm.As a ...
... study based on research in pregnant mice suggest that ... cruciferous vegetables during pregnancy// may show more resistance to ... in their adulthood. ,In this study, researchers ... discovered that a phytochemical administered in pregnant mice, help ...
... receive transfusions during heart bypass surgery have a higher ... their operation. ,In fact, this increased risk ... bypass patients are more likely than men to die ... more likely to receive blood during heart bypass operations, ...
... today welcomed the first formal agreement to deliver a ... the move as a win for patients and doctors ... the first organisation to sign up to deliver the ... rebates immediately after paying the doctor’s bill. ...
Cached Medicine News:Health News:Pioneer Heart Surgeon Faced the Scalpel at 98 2Health News:Pregnant Women- Eat Broccoli And Cabbage 2Health News:Blood Transfusions Raise Heart Patients’ Infection and Death Ris 2Health News:Blood Transfusions Raise Heart Patients’ Infection and Death Ris 3
... VALTRAC™ Single Use Biofragmentable Anastomosis Rings., ... end-to-side and side-to-side anastomosis., ,VALTRAC™ ... multiple intestinal anastomoses but not for ... may be used in any disease ...
... use instrument to create an automatic ... ,The PURSTRING™ 45 disposable instrument has ... and cardiac surgery for temporary and ... PURSTRING™ 65 disposable instrument has application ...
The Auto Suture™ EEA™ 34mm reusable stainless steel sizer has application in intestinal, colorectal and esophageal surgery to help evaluate the diameter of tubular structures....
The Auto Suture™ EEA™ reusable stainless steel sizer set has application in intestinal, colorectal and esophageal surgery to help evaluate the diameter of tubular structures....
Medicine Products: